Gerald L. Hogue - 21 Mar 2023 Form 4 Insider Report for POINT Biopharma Global Inc.

Role
Director
Signature
/s/ William L. Demers, by Power of Attorney for Gerald L. Hogue
Issuer symbol
N/A
Transactions as of
21 Mar 2023
Net transactions value
+$125,014
Form type
4
Filing time
23 Mar 2023, 20:09:32 UTC
Previous filing
28 Nov 2022
Next filing
05 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PNT Common Stock Options Exercise $125,014 +17,936 +490% $6.97 21,596 21 Mar 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PNT Stock Option (Right to Buy) Options Exercise $0 -17,936 -50% $0.000000 17,936 21 Mar 2023 Common Stock 17,936 $6.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As previously reported in a Form 4 filed with the Securities and Exchange Commission on June 30, 2021, the reporting person received an option to purchase 35,872 shares of the issuer's common stock (the "Option"). The Option vested 25% on December 1, 2021 and 25% on December 1, 2022, and will vest 25% on December 1, 2023 and 25% on December 1, 2024.